CD47 Inhibitors Market Projected to Grow Significantly with Emerging Cancer Therapies by 2034 | DelveInsight [Yahoo! Finance]
ALX Oncology Holdings Inc. (ALXO)
Company Research
Source: Yahoo! Finance
the anticipated launch of late-stage pipeline drugs like evorpacept, the growing number of CD47 inhibitors undergoing clinical trials, and the rising collaborations among companies for the development of CD47 inhibitor drugs. LAS VEGAS Oct. 8, 2024 /PRNewswire/ -- DelveInsight's CD47 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging CD47 inhibitors, market share of individual therapies, and current and forecasted CD47 inhibitors market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany France Italy , and Spain ), the United Kingdom , and Japan ]. Key Takeaways from the CD47 Inhibitors Market Report As per DelveInsight's analysis, the total market size of CD47 inhibitors in the 7MM is expected to surge significantly by 2034. Leading CD47 inhibitor companies such as ALX Oncology, Phanes Therapeutics, Pfizer, Akeso Biopharma, ImmuneOnco Biopharma, and others are developing novel CD47 i
Show less
Read more
Impact Snapshot
Event Time:
ALXO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALXO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALXO alerts
High impacting ALX Oncology Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ALXO
News
- Bluejay Therapeutics Announces Expansion of Leadership Team and Board of Directors [Yahoo! Finance]Yahoo! Finance
- ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical OfficerGlobeNewswire
- ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
ALXO
Earnings
- 11/7/24 - Beat
ALXO
Sec Filings
- 11/19/24 - Form 4
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- ALXO's page on the SEC website